Multicellular living organisms and unmodified parts thereof and – Nonhuman animal – Transgenic nonhuman animal
Reexamination Certificate
1999-10-27
2001-06-26
Priebe, Scott D. (Department: 1632)
Multicellular living organisms and unmodified parts thereof and
Nonhuman animal
Transgenic nonhuman animal
C800S003000, C800S008000, C800S014000, C800S018000, C800S025000, C435S320100, C435S325000, C435S455000, C435S006120, C536S023400, C536S024310
Reexamination Certificate
active
06252132
ABSTRACT:
BACKGROUND OF THE INVENTION
This invention relates to a mutant mouse having a defect in an endogenous &agr;4 subunit of the nicotinic acetylcholine receptor and to a transgenic animal based on the mutant mouse. In addition, this invention relates to isolated cells derived from these animals and to the use of the animals in assays for assessing the effects of nicotine and nicotinic agonists and antagonists in these animals and cells. Finally, this invention provides a nucleotide construct for use in generating these animals and cells.
The nicotinic acetylcholine receptor (nAChR) is a pentameric protein that forms a non-selective cation channel at the neuro-muscular junction and in the central nervous system (CNS). The genes encoding the neuronal nicotinic receptor subunits represent a large multigene family consisting of at least eight alpha subunits (&agr;2-9) and three beta subunits (&bgr;2-4). Each subunit has four putative transmembrane-spanning domains (M1-4) and a similar topological structure.
Neuronal receptors form either heteropentamers comprised of a total of 5 subunits: Two alpha subunits (&agr;2, &agr;3, &agr;4, or &agr;6) and three beta subunits (&bgr;2 or &bgr;4) or they are capable of forming homopentamers (&agr;7, &agr;8 or &agr;9) (Refs.
1
and
2
). The binding site for acetylcholine (ACh) is found at the interface between &agr; and &bgr; subunits indicating that both types of subunits contribute to the various pharmacological profiles of neuronal nAChRs (Ref.
3
).
In situ hybridization experiments have shown the neuronal nAChR subunits to have diverse yet overlapping expression patterns in the CNS. &bgr;2 is the most widely expressed subunit in the peripheral nervous system (PNS), while &agr;4 expression is almost as ubiquitous, but &agr;4 is more limited to the CNS with only a small amount of expression seen in the PNS (Refs.
4
and
5
). These findings have been further confirmed by immunoprecipitation experiments, which indicate that in vivo receptors in the CNS are primarily composed of &agr;4 and &bgr;2 subunits (Ref.
6
).
The pharmacology of the nAChRs has been extensively demonstrated with the Xenopus oocyte heterologous expression system (Ref.
7
). This approach is limited, however, as the endogenous composition of nAChRs is still not known. While the rank order of potencies of nicotinic agonists seen in vivo more or less correspond to those observed in vitro, the single channel conductance of nAChR in vivo rarely coincides with the values found in Xenopus oocytes (Ref.
2
).
Another approach to identify the composition of nAChR is to examine the nicotinic responses in knockout animals. This approach has been validated with the &bgr;2 nAChR subunit knockout mice where the &bgr;2 subunit was found to be necessary for a nicotine elicited response in the thalamus, but not in the medial habenula (Ref.
8
). Furthermore, &bgr;2 was found to be a necessary component of the high affinity binding site for nicotine.
Moreover, certain behavioral effects of systemic nicotine are not clearly associated with the activation of particular structures. Nicotine has been demonstrated to act as an enhancer of memory and attention (Ref.
10
), as an antinociceptive (Ref.
11
), and as an anxiolytic (Ref.
12
). The composition of the subunits of the nAChRs that mediate these responses are not known. On the other hand, the activation of nAChR by endogenous ACh in these different behaviors remains to be demonstrated. Thus, there exists a need in the art for a way to examine this contribution by comparison with wild type animals.
Further, because the precise roles of the various subunits of the nAChR are unknown at this time, there exists a need in the art for an animal model to study such roles. The generation of a mutant mouse having defective nAChR subunits would aid in defining the normal roles of the various subunits, and allow an animal model of nAChR deficiency to be used in the design and assessment of chemical approaches to regulating nicotine effects. Such a nAChR modified mutant or transgenic animal could also be used as a source of cells for cell culture.
SUMMARY OF THE INVENTION
This invention aids in fulfilling these needs in the art. More particularly, this invention provides a mutant mouse whose germ cells and somatic cells contain a mutation comprising a disruption of the endogenous &agr;4 subunit of the nicotinic acetylcholine receptor (nAChR) gene. The disrupted &agr;4 subunit of the nAChR gene results in the mouse lacking detectable levels of the endogenous &agr;4 subunit of nAChR without a change in level of expression of other nAChR subunits as compared to a wild type mouse.
In one embodiment of the invention, the disruption can be introduced into the mouse or an ancestor of the mouse via homologous recombination in embryonic stem cells. In another embodiment, the mutation can be introduced into an ancestor of the mouse at an embryonic stage following microinjection of embryonic stem cells into a mouse cell.
In one embodiment, the mouse of the invention can be fertile and can transmit the mutation to its offspring. In another embodiment, the mutant mouse of the invention is post-natal.
The germ cells and somatic cells of the mutant mouse of the invention can additionally comprise a transgene within the disrupted &agr;4 subunit of the nAChR. For instance, the transgene can encode a selectable marker. As examples, the transgene can encode neomycin resistance or diphtheria toxin.
Another embodiment of the invention comprises a mutant mouse homozygous for a disrupted &agr;4 subunit of the mouse nicotinic acetylcholine receptor gene in the central nervous system of the mouse, wherein the receptor gene is disrupted by a selectable marker sequence introduced into the mouse or an ancestor of the mouse by homologous recombination at an embryonic stage. The disrupted &agr;4 subunit of the nAChR gene results in the mouse having a reduced level of the &agr;4 subunit of the nAChR without a change in level of expression of other nAChR subunits as compared to a wild type mouse.
An alternative embodiment of the invention provides a mutant mouse having &agr; and &bgr; subunits of nAChR, wherein the mutant mouse is homozygous or heterozygous for a mutation in the &agr;4 subunit of nAChR. The mutation has been introduced into the mouse or an ancestor of the mouse via homologous recombination in embryonic stem cells. The mouse does not express a functional mouse &agr;4 nAChR subunit. In another embodiment of the invention, the mutant mouse does not express functional mouse &agr;4 and &bgr;2 nAChR subunits.
In addition, the invention provides an isolated cell line derived from the mutant mouse of the invention. In one embodiment, a mouse embryonic stem (ES) cell line comprises a defective &agr;4 subunit of mouse nicotinic acetylcholine receptor (nAChR), wherein the cell line lacks detectable levels of the &agr;4 subunit of nAChR without a change in level of expression of other nAChR subunits as compared to ES cells from a wild type mouse.
Also, this invention provides an &agr;4 subunit of mouse nicotinic acetylcholine receptor (nAChR) DNA knockout construct comprising a selectable marker sequence flanked by DNA sequences homologous to the &agr;4 subunit of mouse nicotinic acetylcholine receptor gene, wherein when the construct can be introduced into a mouse or an ancestor of a mouse at an embryonic stage. The selectable marker sequence can disrupt the nAChR gene in the mouse and can result in the mouse having a reduced level of the &agr;4 subunit of the nAChR without a change in level of expression of other nAChR subunits as compared to a wild type mouse. In one embodiment, the construct can comprise 5′ to 3′, the &agr;4 subunit of the nAChR gene disrupted by a diphtheria toxin-A gene for selection against random integration, and the first 900 bp of exon
5
of the &agr;4 subunit replaced by a gene encoding neomycin. This invention provides a vector comprising the &agr;4 subunit of mouse nicotinic acetylcholine receptor DNA knockout construct.
Still furt
Changeux Jean-Pierre
Marubio Lisa
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
Institut Pasteur
Paras, Jr. Peter
Priebe Scott D.
LandOfFree
Mutant mouse containing a knockout mutation in DNA encoding... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mutant mouse containing a knockout mutation in DNA encoding..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mutant mouse containing a knockout mutation in DNA encoding... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2461187